UNSPSC 51142516: Tolcapone

This classification denotes an antiparkinsonian agent with the molecular formula C14H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CIF6334OLY, chemically known as 3,4-dihydroxy-4-methyl-5-nitrobenzophenone but generally known as tolcapone, which bears US NIH Compound Identifier 4659569. European Medicines Agency schedules Tolcapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11151MIG.

UNSPSC 51142516 Tolcapone (Commodity) appears to show a significant mismatch between its nominal pharmaceutical scope and recent state and local procurement activity. The single recent opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS posted June 30, 2026—solicits naloxone and safe drug deactivation systems, not tolcapone. Naloxone is an opioid antagonist used for overdose reversal; tolcapone is a catechol-O-methyltransferase inhibitor prescribed for Parkinson's disease. The solicitation is explicit in its scope: 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. This represents community health and public safety procurement rather than specialty pharmaceutical treatment for neurological disease. The county is the issuing body; the notice type is IFB with a response deadline of July 26, 2023 (though the posting date is listed as June 30, 2026, creating an internal date inconsistency in the source). Vendors must include shipping and delivery costs, comply with E-Verify and drug-free workplace certification, carry workers' compensation and commercial general liability insurance, and accept a three-month probationary termination clause.

The source provides no additional state or local opportunities tagged under UNSPSC 51142516, and the single record available does not align with tolcapone as a pharmaceutical commodity. Geographic activity is limited to Florida based on this record alone. The code shows little relevant recent activity, and the tagging inconsistency suggests procurement offices may be using this code inaccurately for naloxone and harm-reduction products rather than for tolcapone proper. Business development professionals should verify with issuing bodies whether this code is the correct classification for pharmaceutical procurement in their target jurisdictions before committing resources to monitor it.